News und Analysen
Charles River Laboratories is First CDMO in North America to Receive EMA Approval to Commercially Produce an Allogeneic Cell Therapy Drug Product
Charles River Laboratories, International Inc. (NYSE: CRL) announced it has received regulatory approval, in the form of Good Manufacturing Practice (GMP) certification, to commercially produce
Form 8.3 - The Vanguard Group, Inc.:Mediclinic International plc
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR)
Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2022, and provided an update on the Company’s clinical development programs and regulatory and
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
Pfizer Inc. (NYSE: PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a
MD Medical Group Investments Plc: MD Medical Group announcement of the extraordinary general meeting
Poxel Announces Extended Cash Runway with Debt Restructuring Agreement and Equity-linked Financing Facility
POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including
Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2022
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 3, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Chemed Corporation Declares Quarterly Dividend of 38 Cents
Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 38-cents per share on the Company’s capital stock, payable on September 2, 2022
IMV Re-Establishes Its At-the-Market Facility Under Renewed Base Shelf Prospectus
IMV Inc. (“IMV” or the “Company”) (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
H1 2022: Temporary supply constraints slow down strong demand
Premier, Inc. Declares an Increase to Quarterly Cash Dividend
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors approved a 5% increase to the company’s quarterly cash dividend
Inogen Announces Second Quarter 2022 Financial Results
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results.
“We made meaningful progress advancing
QuidelOrtho Reports Second Quarter 2022 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a leading in vitro diagnostics company, today announced financial results for the second quarter ended July 3, 2022.
The
Puma Biotechnology Reports Second Quarter 2022 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2022. Unless otherwise stated, all comparisons are for the
DGAP-News: Abivax phase 3 program with obefazimod in ulcerative colitis progresses with US IRB approval
Simulations Plus Enters New Collaboration to Enhance Machine Learning Models for Ionization Constants (pKa)
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced it has entered a new collaboration
Navidea Biopharmaceuticals Announces Commencement of Rights Offering Subscription Period and Updated Terms of its Previously Announced Rights Offering
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
IMV Inc. to Announce Second Quarter 2022 Results and Host a Conference Call and Webcast on August 11, 2022
IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
NanoString to Webcast Presentations from Two Upcoming Healthcare Conferences
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast